SCHEMBL23770069

SCHEMBL23770069

O=C(NC1Cc2ccccc2C1)c1nccnc1NS(=O)(=O)C1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ LMNA P02545 2/20 0.38
▸ GRM5 P41594 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.37
▸ HIF1A Q16665 1/20 0.37
▸ CHRNA7 P36544 2/20 0.37
▸ CNR1 P21554 1/20 0.37
▸ CNR2 P34972 1/20 0.37
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ WNT1 P04628 1/20 0.36
▸ DYRK1A Q13627 1/20 0.36
▸ GRM4 Q14833 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31659140 1.00 ALDH1A1 (0.40) ALDH1A1KDM4EGAALMNAGRM5
SCHEMBL23770323 0.84 AAK1 (0.36) ALDH1A1LMNAGRM5CNR1CNR2
SCHEMBL23770108 0.81 ALDH1A1 (0.56) ALDH1A1KDM4EGAALMNAGRM5
SCHEMBL23770089 0.80 KMT2A (0.49) ALDH1A1KDM4EGAAHIF1ANPC1
SCHEMBL30619454 0.80 HPGD (0.44) ALDH1A1KDM4EGAALMNAGRM5
SCHEMBL23203419 0.80 HPGD (0.44) ALDH1A1KDM4EGAALMNAGRM5
SCHEMBL23770087 0.79 CNR1 (0.48) ALDH1A1KDM4EGAALMNAHRH3
SCHEMBL23770352 0.78 CNR1 (0.41) ALDH1A1KDM4EGAALMNAGRM5
SCHEMBL23770114 0.78 ALDH1A1 (0.53) ALDH1A1KDM4EGAALMNAHIF1A
SCHEMBL23770109 0.77 NPC1 (0.46) LMNAHRH3NPC1RAB9AWNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023205272-A1 PYRAZINAMIDE COMPOUNDS THE GENERAL HOSPITAL CORPORATION (US) 2023-10-26 — — WO disclosed
WO-2023205272-A1 PYRAZINAMIDE COMPOUNDS THE GENERAL HOSPITAL CORPORATION (US) 2023-10-26 — — WO disclosed
US-11708353-B2 Inhibitors of prolyl-tRNA-synthetase THE GENERAL HOSPITAL CORPORATION (US) 2023-07-25 — — US disclosed
US-11708353-B2 Inhibitors of prolyl-tRNA-synthetase THE GENERAL HOSPITAL CORPORATION (US) 2023-07-25 — — US disclosed
US-20210253558-A1 Inhibitors of Prolyl-tRNA-Synthetase PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2021-08-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708353-B2 Inhibitors of prolyl-tRNA-synthetase GARS1, AARS1, NSUN3 ALDH1A1 1643/4885KDM4E 2173/4885GAA 188/4885
US-20210253558-A1 Inhibitors of Prolyl-tRNA-Synthetase GARS1, AARS1, TRMT1 ALDH1A1 2372/4885KDM4E 2245/4885GAA 186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback